دورية أكاديمية
Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves.
| العنوان: | Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves. |
|---|---|
| المؤلفون: | Amado LA; Laboratory of Technological Development in Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil., Coelho WLDCNP; Laboratory of Technological Development in Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil., Alves ADR; Laboratory of Technological Development in Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil., Carneiro VCS; Laboratory of Technological Development in Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.; Laboratory of Molecular Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil., Moreira ODC; Laboratory of Molecular Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.; Real Time PCR Platform RPT09A, Laboratory of Molecular Biology and Endemic Diseases, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil., de Paula VS; Laboratory of Molecular Virology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil., Lemos AS; Laboratory of Translacional Neurosciences, Biomedical Institute, Federal University of the State of Rio de Janeiro-UNIRIO, Rio de Janeiro 22290-240, Brazil., Duarte LA; Laboratory of Translacional Neurosciences, Biomedical Institute, Federal University of the State of Rio de Janeiro-UNIRIO, Rio de Janeiro 22290-240, Brazil.; School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Gutman EG; Laboratory of Translacional Neurosciences, Biomedical Institute, Federal University of the State of Rio de Janeiro-UNIRIO, Rio de Janeiro 22290-240, Brazil.; School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Fontes-Dantas FL; Laboratory of Translacional Neurosciences, Biomedical Institute, Federal University of the State of Rio de Janeiro-UNIRIO, Rio de Janeiro 22290-240, Brazil.; Department of Pharmacology and Psychobiology, Roberto Alcântara Gomes Institute Biology (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil., Gonçalves JPDC; Laboratory of Translacional Neurosciences, Biomedical Institute, Federal University of the State of Rio de Janeiro-UNIRIO, Rio de Janeiro 22290-240, Brazil., Ramos CHF; Unit of Intensive Treatment, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Ramos Filho CHF; Unit of Intensive Treatment, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Cavalcanti MG; Epidemiology and Evaluation Service, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Amaro MP; Post-Graduate Program in Infectious and Parasitic Diseases, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Kader RL; Post-Graduate Program in Infectious and Parasitic Diseases, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Medronho RA; School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil., Sarmento DJS; Department of Oral Diagnosis, School of Dentistry, State University of Paraíba, Araruna 58429-500, Brazil., Alves-Leon SV; Laboratory of Translacional Neurosciences, Biomedical Institute, Federal University of the State of Rio de Janeiro-UNIRIO, Rio de Janeiro 22290-240, Brazil.; School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil.; Department of Neurology, Reference and Research Center for Multiple Sclerosis and Other Central Nervous System Idiopathic Demyelinating Inflammatory Diseases, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil. |
| المصدر: | Journal of clinical medicine [J Clin Med] 2023 Mar 29; Vol. 12 (7). Date of Electronic Publication: 2023 Mar 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, [2012]- |
| مستخلص: | Since COVID-19 was declared a pandemic, Brazil has become one of the countries most affected by this disease. A year into the pandemic, a second wave of COVID-19 emerged, with a rapid spread of a new SARS-CoV-2 lineage of concern. Several vaccines have been granted emergency-use authorization, leading to a decrease in mortality and severe cases in many countries. However, the emergence of SARS-CoV-2 variants raises the alert for potential new waves of transmission and an increase in pathogenicity. We compared the demographic and clinical data of critically ill patients infected with COVID-19 hospitalized in Rio de Janeiro during the first and second waves between July 2020 and October 2021. In total, 106 participants were included in this study; among them, 88% had at least one comorbidity, and 37% developed severe disease. Disease severity was associated with older age, pre-existing neurological comorbidities, higher viral load, and dyspnea. Laboratory biomarkers related to white blood cells, coagulation, cellular injury, inflammation, renal, and liver injuries were significantly associated with severe COVID-19. During the second wave of the pandemic, the necessity of invasive respiratory support was higher, and more individuals with COVID-19 developed acute hepatitis, suggesting that the progression of the second wave resulted in an increase in severe cases. These results can contribute to understanding the behavior of the COVID-19 pandemic in Brazil and may be helpful in predicting disease severity, which is a pivotal for guiding clinical care, improving patient outcomes, and defining public policies. |
| References: | Cell Discov. 2020 Feb 24;6:11. (PMID: 32133153) Lancet. 2021 May 1;397(10285):1646-1657. (PMID: 33901420) Signal Transduct Target Ther. 2022 Jul 29;7(1):257. (PMID: 35906201) Cephalalgia. 2018 Jan;38(1):1-211. (PMID: 29368949) Liver Int. 2020 Aug;40(8):1901-1905. (PMID: 32478465) Environ Res. 2022 Jun;209:112816. (PMID: 35093310) Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507) Lancet Reg Health Am. 2022 Jun;10:100221. (PMID: 35309089) Expert Rev Vaccines. 2013 Jul;12(7):759-66. (PMID: 23885821) N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464) JAMA. 2020 Sep 15;324(11):1048-1057. (PMID: 32821939) Clin Infect Dis. 2021 Nov 2;73(9):e2995-e3001. (PMID: 32856036) Acad Emerg Med. 2020 Jul;27(7):612-613. (PMID: 32506683) Clin Microbiol Infect. 2020 Jun;26(6):767-772. (PMID: 32304745) Virus Res. 2022 Jul 2;315:198785. (PMID: 35461905) J Chem Inf Model. 2022 Jan 24;62(2):412-422. (PMID: 34989238) Vaccine. 2010 Nov 29;28(51):8077-84. (PMID: 20974306) Nat Med. 2021 Jun;27(6):1055-1061. (PMID: 33875890) J Neurol. 2021 Mar;268(3):762-769. (PMID: 32749601) Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387) Clin Rheumatol. 2020 Sep;39(9):2789-2796. (PMID: 32720259) J Allergy Clin Immunol. 2020 Oct;146(4):790-798. (PMID: 32810517) Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026) Lancet Respir Med. 2020 Sep;8(9):e70. (PMID: 32771081) Indian J Pediatr. 2020 Apr;87(4):281-286. (PMID: 32166607) J Med Virol. 2022 Jul;94(7):3006-3016. (PMID: 35315098) Int J Mol Sci. 2022 Nov 05;23(21):. (PMID: 36362378) Rev Soc Bras Med Trop. 2020 Apr 17;53:e20200167. (PMID: 32320998) JAMA. 2020 Apr 28;323(16):1612-1614. (PMID: 32191259) PLoS One. 2020 Jul 23;15(7):e0236240. (PMID: 32702044) J Med Virol. 2020 Nov;92(11):2742-2750. (PMID: 32533777) Lancet Infect Dis. 2020 May;20(5):547-548. (PMID: 32311323) Lancet Respir Med. 2020 Dec;8(12):1201-1208. (PMID: 32861276) Drug Dev Res. 2021 Jun;82(4):474-493. (PMID: 33251593) Metabolism. 2020 Jul;108:154244. (PMID: 32320741) J Thromb Haemost. 2020 Jun;18(6):1324-1329. (PMID: 32306492) J Virol. 2022 Apr 27;96(8):e0017722. (PMID: 35389263) Lancet Infect Dis. 2020 Jun;20(6):656-657. (PMID: 32199493) J Med Virol. 2020 Oct;92(10):2188-2192. (PMID: 32436996) Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119. (PMID: 35858386) Am J Gastroenterol. 2021 Jul 1;116(7):1414-1425. (PMID: 33993134) Semin Immunol. 2018 Dec;40:83-94. (PMID: 30501873) ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. (PMID: 32167747) J Hepatol. 2020 Nov;73(5):1231-1240. (PMID: 32553666) Viruses. 2020 Jan 24;12(2):. (PMID: 31991541) Bratisl Lek Listy. 2022;123(6):440-443. (PMID: 35576546) Gastroenterology. 2020 Aug;159(2):768-771.e3. (PMID: 32376408) JAMA Netw Open. 2020 Sep 1;3(9):e2022310. (PMID: 32965502) Leukemia. 2020 Aug;34(8):2163-2172. (PMID: 32528042) Eur Radiol. 2020 Aug;30(8):4381-4389. (PMID: 32193638) Virol Sin. 2021 Oct;36(5):869-878. (PMID: 33661489) JAMA. 2022 Jan 18;327(3):217-218. (PMID: 34989763) Am J Respir Crit Care Med. 2020 Dec 15;202(12):1710-1713. (PMID: 32897754) Allergy. 2021 Mar;76(3):735-750. (PMID: 32762135) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) Alzheimers Dement. 2021 Nov;17(11):1818-1831. (PMID: 33881211) J Hepatol. 2020 Sep;73(3):566-574. (PMID: 32298767) Science. 2020 Sep 4;369(6508):1255-1260. (PMID: 32703910) Life Sci. 2020 Aug 1;254:117788. (PMID: 32475810) Lancet. 2021 Apr 3;397(10281):1265-1275. (PMID: 33773118) Allergy. 2020 Jul;75(7):1564-1581. (PMID: 32396996) J Clin Virol. 2020 Jun;127:104363. (PMID: 32298988) Eur Respir J. 2020 May 14;55(5):. (PMID: 32269089) Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Dec;32(12):1428-1433. (PMID: 33541492) Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205. (PMID: 32603425) J Infect. 2020 Sep;81(3):357-371. (PMID: 32615199) Clin Pharmacol. 2011;3:39-43. (PMID: 22287855) Front Immunol. 2022 Jan 24;12:830527. (PMID: 35140714) BMJ. 2021 Nov 29;375:n2943. (PMID: 34845008) Microbiol Spectr. 2022 Feb 23;10(1):e0236621. (PMID: 35196783) Stroke Vasc Neurol. 2020 Jun;5(2):146-151. (PMID: 32385132) J Infect Public Health. 2023 Jan;16(1):4-14. (PMID: 36446204) Lancet. 2020 Jun 6;395(10239):1763-1770. (PMID: 32442528) Clin Microbiol Infect. 2021 Nov;27(11):1652-1657. (PMID: 34245907) J Neurol. 2021 Dec;268(12):4436-4442. (PMID: 33973106) Infection. 2020 Oct;48(5):773-777. (PMID: 32277408) Allergy. 2021 Feb;76(2):533-550. (PMID: 32662525) Hypertens Res. 2020 Nov;43(11):1267-1276. (PMID: 32855527) Ann Transl Med. 2020 Feb;8(3):48. (PMID: 32154288) Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364. (PMID: 33692570) Cancer Cell. 2020 Nov 9;38(5):661-671.e2. (PMID: 32997958) Microbes Infect. 2020 Nov - Dec;22(10):617-621. (PMID: 32911086) Cochrane Database Syst Rev. 2022 Mar 9;3:CD015125. (PMID: 35262185) Lancet Respir Med. 2021 Apr;9(4):407-418. (PMID: 33460571) Infection. 2021 Feb;49(1):15-28. (PMID: 32860214) Nat Rev Cardiol. 2020 May;17(5):259-260. (PMID: 32139904) Lancet Respir Med. 2021 Aug;9(8):e82-e83. (PMID: 34273268) JAMA Neurol. 2020 Jun 1;77(6):683-690. (PMID: 32275288) Lancet Reg Health Am. 2022 Feb;6:100107. (PMID: 34746913) Virus Evol. 2021 Aug 14;7(2):veab069. (PMID: 34532067) |
| فهرسة مساهمة: | Keywords: COVID-19; epidemic waves; epidemiology; risk factors |
| تواريخ الأحداث: | Date Created: 20230413 Latest Revision: 20230415 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10094970 |
| DOI: | 10.3390/jcm12072568 |
| PMID: | 37048652 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2077-0383 |
|---|---|
| DOI: | 10.3390/jcm12072568 |